Skip to main content

Table 2 Presentation, treatment strategies, and outcomes of patients with endophthalmitis caused by Pseudomonas aeruginosa

From: Characterization of Pseudomonas aeruginosa isolates from patients with endophthalmitis using conventional microbiologic techniques and whole genome sequencing

No. Baseline VA Initial VA Initial Tx Initial IVTI Additional Tx
(Days after presentation)
Additional IVTI
(Days after presentation)
Last VA Follow-up time
1 UK LP T + I Unknown PPV (1) Cfx (2)
Ctz (3)
NLP 2 years
2 UK LP PPV Vanc + Ctz
(intra-op)
Enucleation Enucleation 7 years
3 UK UK UK UK UK UK UK UK
4 UK HM T + I UK Enucleation (6) Enucleation 8 months
5 UK LP T + I Vanc + Ctz + Dex PPV (4) Vanc + Dex (4)
Ctz (8)
CF 3 months
6 UK LP T + I Vanc + Ctz PPV (4) Ctz (2 & 8)
Ctz intra-op (4)
LP 2 days
7 UK LP T + I Ctz + Vanc Vanc + Dex (2)
Vanc + Ctz + Dex (5)
LP 4 years
8 UK HM Globe repair
PPV
Vanc + Ctz + Vcz (intra-op) Retinal detachment repair (4 months) 20/400 2 years
  1. Presentation, treatment strategies, and outcomes of patients with endophthalmitis caused by Pseudomonas aeruginosa in this cohort
  2. Abbreviations: VA visual acuity, NLP no light perception, LP light perception, HM hand motions, UK unknown, Tx treatment, IVTI intravitreal injection, T + I vitreous tap and intravitreal injection, PPV pars plana vitrectomy, Vanc vancomycin, Ctz ceftazidime, Cfx cefuroxime, Dex dexamethasone, Vcz voriconazole, – not applicable